-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Adenosine 5'-monophosphate monohydrate
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/18422-05-4.gif)
| Category | Herpes simplex Virus (HSV) |
| CAS | 18422-05-4 |
| Description | Adenosine 5'-monophosphate monohydrate (5'-AMP) is an activator of a class of protein kinases known as AMP-activated protein kinase (AMPK). |
Product Information
| Synonyms | [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;hydrate |
| IUPAC Name | [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;hydrate |
| Molecular Weight | 365.24 |
| Molecular Formula | C10H14N5O7P·H2O |
| Canonical SMILES | C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)O)O)O)N.O |
| InChI | InChI=1S/C10H14N5O7P.H2O/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20;/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20);1H2/t4-,6-,7-,10-;/m1./s1 |
| InChIKey | ZOEFQKVADUBYKV-MCDZGGTQSA-N |
| Boiling Point | 798.5°C at 760mmHg |
| Melting Point | 183-188 °C (dec.)(lit.) |
| Flash Point | 436.7°C |
| Purity | ≥95% |
| Solubility | In Vitro: H2O : 5 mg/mL(13.69 mM;Need ultrasonic and warming) |
| Appearance | Solid Powder |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Animal Admin | For Adenosine 5'-monophosphate monohydrate (5'-AMP)-pretreated survival experiment, Adenosine 5'-monophosphate monohydrate (5 mg/20 g body weight i.p.) or PBS is administered to mice. For general experiment, WT mice are randomly divided into different groups (n=5 in each group). The liver of each mouse is removed immediately and then is kept at -80°C until analyzed. |
| Exact Mass | 365.073639 |
| In Vitro | Adenosine 5'-monophosphate monohydrate (5'-AMP)-induced cell toxicity is negligible at concentrations of 25 to 400 μM in RAW264.7 cells. It significantly attenuates the mRNA expression of tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 in RAW264.7 cells. Exposure of cells to Adenosine 5'-monophosphate monohydrate significantly reduces recruitment of NF-κB p65 to TNF-α, IL-6, and IL-1β gene promoters. |
| In Vivo | C57BL/6J mice treated with Adenosine 5'-monophosphate monohydrate (5'-AMP) markedly increases hepatic adenosine level. Serum aspartate transaminase (AST) and alanine transaminase (ALT) levels are significantly lowered in the Adenosine 5'-monophosphate monohydrate group than in the vehicle group. The area and extent of necrosis is attenuated and the infiltration of inflammatory cells is reduced in the Adenosine 5'-monophosphate monohydrate group. |
| PSA | 205.11000 |
| Target | Adenosine Receptor; HSV |
| Vapor Pressure | 6.7E-27mmHg at 25°C |
